Published customer image: Enlarge
Goat anti Human CD274 antibody (AHP2128) used for the identification of PD-L1 expression by immunohistochemistry on formalin fixed, paraffin embedded tissue sections.
Immunohistochemical analysis (original magnification?×?200). a CD4+ lymphocytes. b CD8+ lymphocytes. c CTLA4– lymphocytes. d CD68+ cells. e Glial fibrillary acid protein (GFAP) weak positive-reactive astrocytes. f GFAP moderate positive-reactive astrocytes. g Programmed cell death protein 1 receptor (PD-1)-negative expression on stromal tumor infiltrating lymphocytes (TILs) in the brain microenvironment. h PD-1-positive expression on TILs in the brain microenvironment. i PD-L1 negative expression on TILs in brain microenvironment. j Programmed cell death protein 1 receptor ligand (PD-L1)-negative expression in breast cancer brain metastases (BCBM). k PD-L1 weak positive expression in BCBM. l PD-L1 moderate positive expression in BCBM. m PD-L2 negative expression in TILs in the brain microenvironment. n PD-L2 negative expression in BCBM. o PD-L2 weak positive expression in BCBM. p PD-L2 moderate positive expression in BCBM.
From: Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arłukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozłowski W, Kowalczyk A, Loi S, Biernat W, Jassem J; Polish Brain Metastasis Consortium.
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Breast Cancer Res. 2016 Apr 27;18(1):43.